Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ethinylestradiol/Gestodene · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ethinylestradiol/Gestodene (BAY86-5016) | DRUG | 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen |
| Ethinylestradiol/Gestogene (BAY86-5016) | DRUG | 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen |
Inclusion Criteria: * Requiring contraception * Normal cervical smear * Smokers not older than 30 years * History of regular cyclic menstrual periods Exclusion Criteria: * Pregnancy or lactation * Obesity (BMI\> 30 kg/m2 * Significant skin reaction to transdermal preparations or sensitivity to su...
Ethinyl estradiol, Levonorgestrel is a combination of two hormones used for contraception and for the treatment of primary dysmenorrhea. It is being developed by Bayer AG as a small molecule drug and is currently in Phase 3 clinical trials for these indications.
Bayer AG, traded as BAYRY, is developing Ethinyl estradiol, Levonorgestrel. The drug is a small molecule combination product being studied for contraception and primary dysmenorrhea. It has completed four clinical trials with a total enrollment of 2,067 participants.
Ethinyl estradiol, Levonorgestrel is in Phase 3 clinical development. The Phase 3 trial, NCT00909857, studied its effect on primary dysmenorrhea and enrolled 507 participants. The drug is investigational and not yet approved for any indication.
Ethinyl estradiol, Levonorgestrel has completed four clinical trials. NCT00873483 studied ovulation inhibition in obese women, NCT00896571 examined endometrial effects, NCT00909857 evaluated primary dysmenorrhea, and NCT00915915 assessed ovulation inhibition and pharmacokinetics. All trials are completed, with none currently active.
Ethinyl estradiol, Levonorgestrel is being studied in a transdermal patch formulation. Clinical trials NCT00896571 and NCT00915915 evaluated transdermal delivery of ethinyl estradiol combined with other progestins. The drug is also being investigated for oral use in contraception and dysmenorrhea.
Ethinyl estradiol, Levonorgestrel combines an estrogen and a progestin to prevent ovulation and manage menstrual pain. It works by suppressing ovulation for contraception and by reducing prostaglandin-related cramping in primary dysmenorrhea. The drug is being studied in healthy female volunteers across multiple countries.